Q-omics provides the consensus-scored LMX1B profile across patient tissues and cancer cell-line models. LMX1B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LMX1B is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LMX1B RNA expression shows 14,260 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where LMX1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LMX1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LMX1B survival associations across molecular data types. LMX1B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LMX1B RNA expression–survival associations across cancer types. High LMX1B expression shows unfavorable associations in ACC, HNSC, UVM, KIRC, BLCA and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LMX1B RNA expression.
This table summarizes LMX1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LMX1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LMX1B shows lower tumor expression in KIRC, THCA, KIRP and KICH and higher tumor expression in HNSC and BRCA. The KIRC box plot shows higher LMX1B RNA expression in normal versus tumor tissue (log2 FC = −2.534, t-test p < 0.001).
This table shows molecular features associated with LMX1B in patient tissues and cancer cell lines. In patient samples, LMX1B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LMX1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
